📰 **Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal **

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) announced the presentation of new data from a clinician survey highlighting the functional impact of INGREZZA capsules on patients with mild tardive dyskinesia (TD) at American Psychiatric Association(APA) 2026 meeting. In addition,...

🔗 https://www.nasdaq.com/articles/neurocrine-unveils-new-ingrezza-findings-mild-tardive-dyskinesia-apa-2026-closes-soleno

#markets #news